Form 4: Dyne Therapeutics Executive Acquires Shares and Options
SEC Form 4 Filing
Richard William Scalzo, SVP, Head of Finance & Admin at Dyne Therapeutics, acquired shares and stock options on December 4, 2024.
Summary
- Richard William Scalzo, a senior executive at Dyne Therapeutics, acquired 32,700 shares of common stock through restricted stock units (RSUs) and 52,300 stock options on December 4, 2024.
- The RSUs vest in equal quarterly installments over four years, starting March 4, 2025.
- The stock options vest in equal monthly installments over four years, starting December 4, 2024, and expiring on December 3, 2034.
- Following these transactions, Mr. Scalzo beneficially owns 128,533 shares of common stock, including unvested RSUs, and 52,300 stock options.
Sentiment
Score: 7
Explanation: The document reflects standard executive compensation practices, which is generally viewed as neutral to positive. The acquisition of shares and options by an executive can be seen as a sign of confidence in the company.
Positives
- The acquisition of shares and options by a senior executive could be seen as a positive sign of confidence in the company's future.
Industry Context
This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders make transactions in their company's securities. It provides transparency into executive compensation and ownership.
Comparison to Industry Standards
- The vesting schedules for the RSUs and stock options are typical for executive compensation packages in the biotechnology industry.
- Four-year vesting periods are common to incentivize long-term performance and retention.
- The exercise price of $29.44 for the stock options is a standard practice, often set at or near the market price at the time of grant.
Stakeholder Impact
- The transaction may have a minor positive impact on shareholder sentiment, as it indicates executive confidence in the company.
Key Dates
| Date | Description |
|---|---|
| 12/04/2024 | Date of the transaction where shares and stock options were acquired. |
| 12/04/2024 | Date the stock options were granted. |
| 03/04/2025 | First vesting date for the restricted stock units. |
| 12/04/2028 | End of the vesting period for the stock options. |
| 12/03/2034 | Expiration date for the stock options. |
Keywords
Dyne Therapeutics, Richard Scalzo, stock options, restricted stock units, RSUs, executive compensation, insider trading, beneficial ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.